Raymond James on Bristol-Myers Squibb Co. (BMY): 'we do not view the ZEPHYR data as signaling a risk to Cobenfy across indications'

July 27, 2026 2:29 PM

Raymond James analyst Sean McCutcheon reiterated a Market Perform rating on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst comments "In sum ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Raymond James on Bristol-Myers Squibb Co. (BMY): 'we do not view the ZEPHYR data as signaling a risk to Cobenfy across indications'

Categories